After Ethics committee’s approval, clinical study will be registered on CTRI website. Subjects [(male and females age between 18 – 60 years, (both inclusive)] attending OPD of respective study sites without ongoing antibiotic treatment for UTI and meeting other inclusion and exclusion criteria will be recruited in the study. Intended to get 30 evaluable cases at the end of the study.

 On screening visit (day -5), a written informed consent will be obtained from subject for his/her participation in the study. Subject will undergo physical and systemic examinations. Subject’s medical and surgical history will be taken. Subject’s current medication will be noted in the CRF. Subject’s investigations [CBC, Serum uric acid LFT, RFT] will be done. Clinical symptoms like burning micturition, intermittent urination and pain during urination will be assessed. Subjects will be advised to refrain from any Nutraceutical, Ayurvedic, homeopathic, Siddha, Unani etc. treatment for the same. Throughout study period, subjects will be advised lifestyle modification (nutritious diet, exercise etc.) The record of the current medication will be kept in the CRF. Subject will be called on baseline visit (day 0).

 On baseline visit, subjects will be recruited if he/she meets all the inclusion criteria. Subjects will undergo general and systemic examinations. Clinical signs and symptoms (if any) will be evaluated on subjective assessment scale, Subject will be given study medication packed in HDPE bottle (each containing 60 tablets). Subject will be advised to take study medication in a dose of 1 tablet twice daily orally after each meals with water for next 90 days. Subject will be called for follow up on day 30, day 60, day 90 i.e. till end of study. Subjects who continuously misses dosing for >3 consecutive days or total missed dose >6 days during the study period will be treated as drop outs. Subjects will be allowed to come for follow up either 5 days prior or after the scheduled follow up visit, provided subject should continue the given treatment.

 On every follow up visit, subjects will undergo general and systemic examinations. Clinical symptoms like burning micturition, intermittent urination and pain during urination will be assessed. Patient will be assessed for presence of any adverse events.

 On last follow up visit, subject’s global evaluation for overall improvement and Investigator’s global evaluation for overall improvement will be done. Tolerability of the study drug will be assessed by the investigator and patient at the end of the study. All the subjects will be closely monitored for any adverse events/ adverse drug reactions from baseline visit till the end of the study. On final follow up visit (i.e. day 90), Clinical symptoms like burning micturition, intermittent urination and pain during urination will be assessed. Subjects will be asked to stop trial medication after completion of 90 days of the study treatment and take investigator’s advice for further treatment